DrugPatentWatch Database Preview
Details for Biologics License Application: 125431
Email this page to a colleague
See Plans and PricingSummary for BLA: 125431
| Tradename: | TANZEUM |
| Applicant: | Glaxosmithkline Llc |
| Ingredient: | albiglutide |
| Patents: | 56 |
| Approval Date: | Apr 15, 2014 |
| Suppliers: see list | 1 |
Pharmacology for BLA: 125431
| Drug Class | GLP-1 Receptor Agonist |
| Mechanism of Action | Glucagon-like Peptide-1 (GLP-1) Agonists |
US Patents for BLA: 125431
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | TANZEUM | albiglutide | INJECTABLE;INJECTION | 125431 | 001 | 2014-04-15 | Start Trial | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | 2030-05-05 | RX | search | |
| Glaxosmithkline Llc | TANZEUM | albiglutide | INJECTABLE;INJECTION | 125431 | 001 | 2014-04-15 | Start Trial | Rani Therapeutics, LLC (San Jose, CA) | 2030-12-23 | RX | search | |
| Glaxosmithkline Llc | TANZEUM | albiglutide | INJECTABLE;INJECTION | 125431 | 001 | 2014-04-15 | Start Trial | Pfizer Inc. (New York, NY) | 2039-02-26 | RX | search | |
| Glaxosmithkline Llc | TANZEUM | albiglutide | INJECTABLE;INJECTION | 125431 | 001 | 2014-04-15 | Start Trial | Rani Therapeutics, LLC (San Jose, CA) | 2029-12-24 | RX | search | |
| Glaxosmithkline Llc | TANZEUM | albiglutide | INJECTABLE;INJECTION | 125431 | 001 | 2014-04-15 | Start Trial | Rani Therapeutics, LLC (San Jose, CA) | 2029-12-24 | RX | search | |
| Glaxosmithkline Llc | TANZEUM | albiglutide | INJECTABLE;INJECTION | 125431 | 001 | 2014-04-15 | Start Trial | REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) | 2035-10-12 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
